financetom
Business
financetom
/
Business
/
Lucid Q4 Earnings: Revenue Beat, EPS Beat, 20K Production Guidance For 2025, CEO Transition And More
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lucid Q4 Earnings: Revenue Beat, EPS Beat, 20K Production Guidance For 2025, CEO Transition And More
Feb 25, 2025 1:44 PM

Lucid Group Inc ( LCID ) reported fourth-quarter financial results after the market close on Tuesday. Here’s a rundown of the report.

Q4 Earnings: Lucid reported fourth-quarter revenue of $234.5 million, beating the consensus estimate of $214.22 million, according to Benzinga Pro. The electric vehicle maker reported a fourth-quarter loss of 22 cents per share, beating analyst estimates for a loss of 27 cents per share.

Lucid said it produced 3,386 vehicles in the fourth quarter and delivered 3,099 vehicles. The company ended the quarter with approximately $6.13 billion in total liquidity.

“We saw significant momentum in 2024 with four consecutive quarters of record deliveries,” said Gagan Dhingra, Interim CFO of Lucid.

“Additionally, we made substantial progress in improving our gross margins, managing our operating expenses while balancing strategic growth investments, and strengthening our balance sheet with the support of the Public Investment Fund (PIF).”

Related Link: Polestar Attempts To Woo Disgruntled Tesla Owners With Offers: ‘2025 To Be Strongest Year In Polestar’s History’

Guidance: Lucid said it expects to produce approximately 20,000 vehicles in 2025.

Lucid also announced that CEO and CTO Peter Rawlinson decided to step away from his roles and transition to a strategic technical advisor to the chairman of the company’s board. COO Marc Winterhoff has been appointed Interim CEO.

Lucid executives will further discuss the quarter on a conference call with investors and analysts at 5:30 p.m. ET.

LCID Price Action: Lucid shares were up 8.05% in after hours, trading at $2.82 at the time of publication Tuesday, according to Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved